This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
Chapter 14. Impact of Changes in Antibiotic Use Practices on Nosocomial Infections and Antimicrobial Resistance—Clostridium difficile and Vancomycin-resistant Enterococcus (VRE)
Ebbing Lautenbach, M.D., M.P.H., MSCE
University of Pennsylvania School of Medicine
As discussed in the chapters on handwashing and barrier precautions (Chapters 12 and 13), hospital infection control has historically focused on preventing the transmission of nosocomial pathogens—either from patient to patient or from provider to patient. The potential role of overseeing hospital-wide antibiotic use as an infection control measure has also been recognized for many years.1 With the widespread emergence of nosocomial antibiotic-resistant infections over the past 10-15 years, institutional efforts to control antibiotic use have become a priority for infection control.2,3
The practices reviewed in this chapter involve institutional efforts to control antibiotic use as a means of controlling complications of antibiotic overuse or misuse. In evaluating the potential benefits of these practices, the focus is on the impacts of antibiotic use on infections with vancomycin-resistant enterococci (VRE)4 and Clostridium difficile.5 These pathogens represent two of the most important nosocomial pathogens with relationships to inappropriate antibiotic use. Moreover, as suggested by recent evidence, infection with C. difficile may represent a risk factor for infection with VRE.6
Interventions designed to limit the use of antibiotics may take many forms. Specific practices reviewed in the chapter include:
- Infectious diseases physician approval1—all requests for an antibiotic are discussed with an infectious diseases physician who decides whether use is appropriate.
- Monitoring of antibiotic use by pharmacy service8—pharmacists monitor the use of certain antibiotics and make recommendations for changes to the prescriber.
- Guidelines for antimicrobial use8—dissemination to physicians of guidelines describing appropriate and inappropriate use.
- Therapeutic substitution9—use of one agent replaced by another agent with similar spectrum of activity.
- Computer-assisted prescribing10—computer-based restriction of agent with extra prompts requesting documentation of indication for agent.
- Antibiotic-management program (AMP)11—continuation of antibiotic after a specific duration requires approval from either an infectious diseases physician or pharmacist on the AMP.
Prevalence and Severity of the Target Safety Problem
This chapter focuses on 2 of the most important nosocomial pathogens: VRE and C. difficile. VRE currently accounts for greater than 25% of all nosocomial enterococci4 and confers an increased risk of death, independent of comorbid conditions that may have initially led to the infection.12 VRE infections are also associated with significantly higher hospital costs than those due to vancomycin-sensitive enterococci (VSE)12 (see Chapter 13). C. difficile represents the major, if not only, important infectious cause of nosocomial diarrhea.5 Although death attributable to C. difficile occurs in less than 5% of patients,17 the impact of C. difficile infection remains significant. Patients may require substantially longer lengths of hospital stay—upwards of 18-30 days,18,19 with exploratory and therapeutic surgical procedures required in severe cases.20 It has also been suggested that more debilitated patients (e.g., in rehabilitation centers or long-term care facilities) may be at even greater risk for increased morbidity and mortality due to C. difficile infection.21 The costs associated with C. difficile diarrhea, while not well described, are estimated to be as high as $10,000 per patient22 (see Chapter 13).
Opportunities for Impact
Over half of all hospitalized patients are treated with antibiotics.23 The antibiotics represent a significant portion of overall healthcare costs, accounting for between 20% and 50% of total hospital drug expenditures.23 It has been estimated that 50% of all antibiotics prescribed are either at the wrong dose, the wrong drug, or taken for the wrong duration.24,25 These findings suggest that there is significant room for improvement in antibiotic prescribing practices.
Most hospitals employ formulary restrictions for certain medications (particularly expensive agents, selecting one drug from a group of equivalent agents). However, only a minority of hospitals uses formulary restrictions to limit the use of entire antibiotic classes or specific agents. Those hospitals that do employ antimicrobial formulary restrictions most often do so as a means of controlling costs, rather than as an infection control measure.26 Thus, there remain substantial opportunities to expand upon these existing formulary programs to control the emergence of antimicrobial resistance.
A structured search of the PubMed database (including MEDLINE) and review of the bibliographies of relevant articles identified 10 studies that have examined methods to change antibiotic use with respect to VRE and/or C. difficile infection (Table 14.1). All of these studies were before-after observational cohort studies (Level 3) in which baseline data regarding incidence of VRE or C. difficile were obtained during an observational period and compared with a second time period after an intervention had been implemented. Data on baseline comparability of the before and after groups were not reported in 6 studies.8-11,21,27 Two studies only reported similar admission and census rates during the before and after time periods,7,28 while 2 studies compared patients in the 2 time periods on the basis of numerous variables.29,30
All of the studies reviewed reported changes in the clinical incidence or prevalence of either VRE or C. difficile as a result of antibiotic practice interventions (Level 1). Studies investigating C. difficile measured clinical infections.11 Studies investigating VRE examined VRE infection or VRE colonization.8-10,27
Evidence for Effectiveness of the Practice
Of the 10 studies listed in Table 14.1, all but 38,11,21 showed significant reductions in the incidence of C. difficile or VRE following practice changes. Several possibilities may explain the negative findings of these 3 studies. First, the interventions analyzed might not have produced significant alterations in antibiotic use, so that infection rates with the target pathogens remained unchanged. Second, it is possible that patient-to-patient spread of these pathogens limited the efficacy of the interventions, as this mode of transmission is well known to occur for both VRE and C. difficile, usually via the hands of healthcare workers (see also Chapter 13).31,32 Third, since environmental contamination occurs with both these pathogens, successful control of these organisms may require enhanced disinfection procedures in some cases.33,34 Targeting antibiotic use may not be sufficient to reduce incidence of these pathogens since a significant number of infected or colonized patients may serve as reservoirs. Under this scenario, the argument for barrier precautions as an adjunct measure to prevent spread of organisms from patient to patient becomes more persuasive (see Chapter 13). Indeed, although changes in antibiotic use practice were the primary intervention in all of the studies reviewed here, one study included a component of enhanced barrier precautions in the intervention.21 Future studies should investigate the impact of such multifaceted interventions, both for VRE and C. difficile as well as for other nosocomial pathogens.
Other Potential Benefits
Although not the focus of this chapter, the practices reviewed here may have a beneficial impact on other emerging nosocomial pathogens strongly associated with inappropriate antibiotic use, such as extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae.35 In addition, although we have focused on control of VRE as an end in itself, a primary motivation to achieve this goal is the need to delay the emergence of vancomycin-resistance in Staphylococcus aureus.36,37 As S. aureus represents the most common nosocomial infection,38 the development of high-level vancomycin resistance among staphylococci would constitute a public health disaster.39
Thus, practices that decrease the prevalence of VRE may play an important, albeit indirect, role in preventing or delaying this occurrence.
Potential for Harm
Few of the reviewed studies reported any assessment of possible harm as a result of the antibiotic use practice interventions. One potential result of interventions designed to reduce the use of one antibiotic, or antibiotic class, is the subsequent increase in the use of another class of agents to compensate. In fact, one reviewed study7 noted an increase in the use of other anti-anaerobic agents as clindamycin use decreased. Whether changes in antibiotic use results in changes in antimicrobial susceptibilities, either in the pathogen under study (e.g., VRE, C. difficile) or in other nosocomial pathogens, it is a fertile ground for future study.
Finally, efforts to decrease use of certain antibiotics might increase infection rates due to inappropriate withholding of appropriate antibiotics. However, one reviewed study10 noted no increase in rates of surgical site infections following decrease in the use of vancomycin for preoperative prophylaxis (see also Subchapter 20.1).
Costs and Implementation
The costs of implementing a program to alter antibiotic use practices must be balanced against potential cost savings. Sources of savings may be reduced antibiotic use, use of less expensive agents rather than the more expensive newer agents, and potentially, reduced costs due to decreased incidence of nosocomial infections as a result of interventions. Although several studies reported cost savings due only to decreased antibiotic use,10,11,29 analyses taking into account costs related to subsequent infections (or infections prevented) have been sparse. One study noted that cost savings from decreased use of clindamycin offset the expenditures due to increased use of other antibiotics.7 The authors suggested that if each case of C. difficile resulted in a cost of $2000, the savings to the hospital of the intervention could approach $162,000 annually based on the number of cases averted.7
Another cost of antibiotic use interventions is the expense of ongoing monitoring of antibiotic use and antimicrobial susceptibilities of nosocomial pathogens. Effective recommendation of certain antimicrobial agents over others requires access to (and financial and logistic support for) routine antimicrobial susceptibility testing. Monitoring institutional resistance patterns is vital in order to make required formulary changes in response to emerging resistance patterns and to determine the most effective agents given prevailing susceptibility patterns.
Given the strong association between antibiotic use and subsequent infection (demonstrated for both C. difficile and VRE), it is not surprising that changes in antibiotic use practices can reduce the incidence of infection with these 2 pathogens. The majority of reviewed studies demonstrated a significant reduction in the incidence of VRE or C. difficile following interventions to change antibiotic use practice. While these studies all demonstrated short-term success, future studies should confirm the efficacy of such interventions over the long term. In addition, the effectiveness and feasibility of combining antibiotic practice strategies with efforts to enhance barrier precautions (Chapter 13) should be investigated. Finally, the cost-effectiveness of such strategies (taking into account both the costs associated with monitoring and maintaining sound antibiotic use practices and the costs associated with nosocomial antibiotic-resistant infections) should be investigated.
Table 14.1. Before-after studies of practices to improve antibiotic use*
|Study Setting and Intervention
||Results: before vs. after practice
|Elderly care unit of a large teaching hospital in England, 1984-85; Changes in empiric antibiotic regimens29
||C. difficile infections decreased from 37 to 16 cases (p=0.002).
|Chronic care facility in Baltimore, 1985-86; multifaceted intervention21
||Patients with C. difficile toxin decreased from 28% to 24% (p=NS); Patients with C. difficile culture increased from 33% to 42% (p=NS)
|Veterans Affairs Medical Center in Arizona, 1990-92; restriction of clindamycin use28
||C. difficile infections decreased from 7.7 to 1.9 cases/month (p<0.001)
|660-bed Veterans Affairs hospital in California, 1992-94; removal of antibiotic restrictions30
||Monthly incidence of C. difficile infections per 1,000 admissions increased from 3.4 to 6.2 (p<0.05)
|703-bed Veterans Affairs Medical Center in Virginia, 1993-94; restriction of clindamycin use7
||C. difficile infections decreased from 11.5 to 3.33 cases/month (p<0.001)
|557-bed academic medical center in Maryland, 1994; restriction of vancomycin use8
||Mean monthly prevalence of VRE decreased from 26% to 25% (p=NS)
|35-bed hematologic malignancy unit in a large medical center in England, 1994-95; sequential antimicrobial formulary changes9
||VRE colonization for phases 1, 2, and 3 were 57%, 19%, 36%, respectively (p<0.001 for phase 1 vs. 2; p=0.08 for phase 2 vs. 3)
|Large academic medical center in Virginia, 1994-95; computer-based restriction of vancomycin use10
||VRE colonization decreased (p<0.001, test for trend)
|310-bed Veterans Affairs medical center in New York, 1995; restriction of multiple antibiotics27
||Point prevalence of VRE decreased from 42% to 15% (p<0.001)
|725-bed teaching hospital in Philadelphia, 1995-96; restriction of vancomycin use11
||Incidence of VRE was unchanged at 30% (p=NS)
* NS indicates not statistically significant; VRE, vancomycin-resistant entercocci.
1. Kunin CM, Tupasi T, Craig WA. Use of antibiotics. A brief exposition of the problem and some tentative solutions. Ann Intern Med 1973;79:555-560.
2. Gaynes R. The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin North Am 1997;11:757-765.
3. Goldmann DA, Huskins WC. Control of nosocomial antimicrobial-resistant bacteria: a strategic priority for hospitals worldwide. Clin Infect Dis 1997;24:S139-145.
4. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342:710-721.
5. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027-1036.
6. Roghmann MC, McCarter RJ, Brewrink J, Cross AS, Morris JG. Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia. Clin Infect Dis 1997;25:1056-1059.
7. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998;128:989-995.
8. Morris JG, Shay DK, Hebden JN, McCarter RJ, Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250-259.
9. Bradley SJ, Wilson ALT, Allen MC, Sher HA, Goldstone AH, Scott GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999;43:261-266.
10. Anglim AM, Klym B, Byers KE, Scheld WM, Farr BM. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium. Arch Intern Med 1997;157:1132-1136.
11. Morgan AS, Brennan PJ, Fishman NO. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant enterococcus. Ann Pharmacother 1997;31:970-973.
12. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998;158:522-527.
13. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients: evidence of colonized new admissions as the source of infection. J Infect Dis 1992;166:561-567.
14. Wilcox MH, Smyth ETM. Incidence and impact of Clostridium difficile infection in the UK, 1993-1996. J Hosp Infect 1998;39:181-187.
15. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis in adults: a prospective case-controlled epidemiologic study. Arch Intern Med 1986;146:95-100.
16. Yablon SA, Krotenberg, Fruhmann K. Clostridium difficile-related disease: evaluation and prevalence among inpatients with diarrhea in two freestanding rehabilitation hospitals. Arch Phys Med Rehabil 1993;74:913.
17. Olson MM, Shanholtzer CJ, Lee JT, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994;15:371-381.
18. MacGowan AP, Brown I, Feeney R, Lovering A, McCulloch SY, Reeves DS. Clostridium difficile associated diarrhea and length of hospital stay. J Hosp Infect 1995;31:241-244.
19. Riley TV, Codde JP, Rouse IL. Increase length of stay due to Clostridium difficile associated diarrhoea. Lancet 1995;345:455-456.
20. Kent KC, Rubin MS, Wroblewski L, Hanff PA, Sline W. The impact of Clostridium difficile on a surgical service. Ann Surg 1998;227:296-301.
21. Bender BS, Laughon BE, Gaydos C, Forman MS, Bennett R, Greenough WB, et al. Is Clostridium difficile endemic in chronic-care facilities? Lancet 1986;2:11-13.
22. Spencer RC. Clinical impact and associated costs of Clostridium difficile-associated disease. J Antimicrob Chemother 1998;41(Suppl C):C5-C12.
23. Pestotnik SL, Classen DC, Evans RS. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996;124:884-890.
24. Yates RR. New intervention strategies for reducing antibiotic resistance. Chest 1999;115:24S-27S.
25. Piquette RK. A targeted review of vancomycin use. Can J Hosp Pharm 1991;44:83-7.
26. John JF, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997;24:471-485.
27. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23:1020-1025.
28. Pear SM, Williamson TH, Bettin KM, Gerding DN, Galgiani JN. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994;120:272-277.
29. McNulty C, Logan M, Donald IP, Ennis D, Taylor D, Baldwin RN, et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 1997;40:707-711.
30. Ho M, Yang D, Wyle FA, Mulligan ME. Increased incidence of Clostridium difficile-associated diarrhea following decreased restriction of antibiotic use. Clin Infect Dis 1996;23(suppl 1):S102-S106.
31. Handwerger S, Raucher B, Altarac D, Monka J, Marchione S, Singh KV, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993;16:750-755.
32. Chang VT, Nelson K. The role of physical proximity in nosocomial diarrhea. Clin Infect Dis 2000;31:717-722.
33. Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000;31:995-1000.
34. Byers KE, Durbin LJ, Simonton BM, Anglim AM, Adal KA, Farr BM. Disinfection of hospital rooms contaminated with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1998;19:261-264.
35. Jacoby GA. Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams. Infect Dis Clin North Am 1997;11:875-887.
36. Michel M, Gutmann L. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet 1997;349:1901-1906.
37. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999;340:493-501.
38. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998;26:1179-1181.
39. Edmond MB, Wenzel RP, Pasculle AW. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med 1996;124:329-334.
Return to Contents
Proceed to Next Chapter